Sign In
Buy INO
$1.14
-0.0700 (-5.79%)
At Close: Jun 03, 2026
Long-lasting in vivo antibody production: DMAb levels remained stable for 72 weeks in all participants (n=24) who have reached that timepoint No anti-drug antibodies (ADA): no immune rejection of the
INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025
12:55pm, Wednesday, 12'th Mar 2025
PLYMOUTH MEETING, Pa. , March 12, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-a
Inovio Pharmaceuticals Inc (INO) Oppenheimer 35th Annual Healthcare Life Sciences Conference (Transcript)
05:39pm, Wednesday, 12'th Feb 2025
Inovio Pharmaceuticals Inc (NASDAQ:INO ) Oppenheimer 35th Annual Healthcare Life Sciences Conference February 12, 2025 3:20 PM ET Company Participants Jacqui Shea - CEO and President Conference Call P
Here's Why Inovio (INO) Could be Great Choice for a Bottom Fisher
10:55am, Wednesday, 12'th Feb 2025
Inovio (INO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend
Data shows that INO-3107 induced new populations of T cells in the blood that traveled to airway tissue and were associated with clinical benefit as measured by reduced need for surgeries PLYMOUTH MEE
Poster will describe loss of detectable HPV-6 in Recurrent Respiratory Papillomatosis patients following treatment with INO-3107 PLYMOUTH MEETING, Pa. , Feb. 10, 2025 /PRNewswire/ -- INOVIO (NASDAQ:
INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
04:14pm, Wednesday, 29'th Jan 2025
PLYMOUTH MEETING, Pa. , Jan. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-ass
INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments
08:04am, Thursday, 09'th Jan 2025
PLYMOUTH MEETING, Pa. , Jan. 9, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-rel
Gold Down Over 1%; Inovio Pharmaceuticals Shares Plummet
02:10pm, Friday, 13'th Dec 2024
U.S. stocks traded mixed toward the end of trading, with the S&P 500 edging lower on Friday.
INOVIO Announces Pricing of $30 Million Public Offering
07:00am, Friday, 13'th Dec 2024
PLYMOUTH MEETING, Pa. , Dec. 13, 2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prot
INOVIO Announces Proposed Public Offering
04:01pm, Thursday, 12'th Dec 2024
PLYMOUTH MEETING, Pa. , Dec. 12, 2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prot
Data from a retrospective trial evaluating the longer-term benefit of INO-3107 to patients with Recurrent Respiratory Papillomatosis (RRP) involved in a Phase 1/2 trial showed the number of patients w
INOVIO Reports Inducement Grant Under Inducement Plan
04:02pm, Friday, 29'th Nov 2024
PLYMOUTH MEETING, Pa. , Nov. 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-r
European And US Vaccine Stocks Are Under Pressure - Here's WHy
11:21am, Friday, 15'th Nov 2024
Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services.
Inovio Pharmaceuticals, Inc. (INO) Q3 2024 Earnings Call Transcript
07:53pm, Thursday, 14'th Nov 2024
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q3 2024 Earnings Call Transcript November 14, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of IR Jacqui Shea - President and CEO Mike Sumner -
